Analyst Conference Summaries

Biotechnology Investor Aids

Biomarin Pharmaceuticals
BRMN

conference date: February 21, 2019 @ 1:30 PM Pacific Time

FDA Approves BioMarin's Palynziq for PKU [FDA, 5/24/2018]

Pharmacyclics, BioMarin, And Incyte: A Quick Screen [Seeking Alpha, 3/26/2015]

2019
 
 
 
Feb. 21, 2019
 
 
 
2018
Not Available
Q3 2018
Feb. 22, 2018
April 25, 2018
August 2, 2018
Oct. 25 2018
2017
Feb. 23, 2017
May 4, 2017  
August 2, 2017
Oct. 26, 2017
2016
 Biomarin Q3 not covered
02/25/2016
04/28/2016
08/04/2016
10/27/2016

Biomarin Pharmaceuticals (BRMN) is commercial stage biotechnology company specializing in therapies for rare disorders (orphan drugs).

Biomarin Pharmaceuticals web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 ISRG
 MCHP
 MYL.
 PLX
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2016 William P. Meyers